Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which scarring occurs to the glomeruli. Patients with FSGS typically present with nephrotic syndrome, involving edema and proteinuria, but they may also have hypertension, microscopic hematuria, and renal insufficiency at the time of presentation. Owing to FSGS’s various etiologies and differences in presentation, management of the disease must be individualized. RAAS inhibitors are often initiated to reduce proteinuria, and diuretics are commonly used to treat symptoms. Corticosteroid and immunosuppressive therapies are also considered in FSGS associated with clinical features of the nephrotic syndrome.
Markets covered: United States.
Key drugs: alkylating agents, corticosteroids, diuretics, RAAS inhibitors.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.